In order to investigate whether the reduction in stemness genes increases the sensitivity of CD133+ GBM to chemotherapy, we treated CD133+ GBM cells with varying concentrations of TMZ along with shRNA gene cassettes targeting NANOG or OCT4. This evidence concerns the gene POU5F1 and glioblastoma.